See more : Yash Chemex Limited (YASHCHEM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pomifrutas S/A (FRTA3.SA) Income Statement Analysis – Financial Results
- Cheetah Canyon Resources Corp. (CRRDF) Income Statement Analysis – Financial Results
- SillaJen, Inc. (215600.KQ) Income Statement Analysis – Financial Results
- Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) Income Statement Analysis – Financial Results
- Suzhou Secote Precision Electronic Co.,LTD (603283.SS) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
| General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
| Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
| Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO)...
The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Valued at about $79.3 billion at the moment, it's expected to balloon to $503.4 billion by the time 2030 rolls around, according to Statista.
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for...
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide...
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its...
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
Keep an eye on machine learning stocks. Companies are tripping over each other for the technology, which involves feeding data to a machine so it can learn and even make human-like decisions.
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched...
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be...
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has received...
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports